FDA Granted Priority Review for Elinzanetant Application

The drug seeks approval to treat vasomotor symptoms in breast cancer patients receiving endocrine therapy.

Updated on Sept. 28, 2026 in Cancer

FDA Granted Priority Review for Elinzanetant Application

Live Poll

Do you trust that pharmaceutical companies are doing enough to address breast cancer treatment side effects?

The U.S. FDA has accepted a supplemental New Drug Application for elinzanetant and granted it Priority Review. This move initiates the regulatory process to potentially approve the drug for treating vasomotor symptoms in breast cancer patients undergoing endocrine therapy.

Why it matters

Currently, there are no FDA-approved treatment options available for patients experiencing vasomotor symptoms while receiving endocrine therapy for breast cancer. If approved, this drug would address a significant unmet medical need for this patient population.

The OASIS-4 trial enrolled 474 women aged 18 to 70 and compared 60mg doses of elinzanetant against a placebo over a 52-week period. The study included 316 participants receiving the treatment and 158 initially assigned to the placebo group.

The players

U.S. Food and Drug Administration

This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.

Bayer

This multinational pharmaceutical and life sciences company is the developer of elinzanetant and is headquartered in Whippany, N.J.

The details

The supplemental application is based on findings from the 52-week, double-blind, randomized placebo-controlled OASIS-4 study. While elinzanetant showed a reduction in vasomotor symptoms compared to the placebo, common adverse events reported in the trial included headache, fatigue, and somnolence.

June 2025: OASIS-4 trial findings were published in NEJM.
October 2025: FDA approved elinzanetant for menopausal hot flashes.
September 28, 2026: Bayer announced the FDA accepted the supplemental application.

Cancer
Sept. 18
FDA Approved New Breast Cancer Combination Therapy
Cancer
Sept. 21
FDA Conditionally Accepted Name for Lirafugratinib
Diabetes
Sept. 18
FDA Approved Generic Lanreotide Injection

The Big Picture

The FDA's Priority Review designation program for this oncology support drug accelerates the standard regulatory timeline, mirroring a pattern seen in other high-need therapeutic areas. The application follows the established regulatory pattern of expediting review for treatments that address serious conditions with no current approved therapies.

Breast cancer patients currently struggling with vasomotor symptoms during endocrine therapy may soon have a new therapeutic option if the FDA grants final approval. The potential availability of this drug represents a new path for managing side effects without disrupting standard cancer care.

The takeaway

The progression of elinzanetant into the regulatory review phase marks a potential breakthrough for managing common side effects in long-term endocrine therapy. Patients currently on these therapies should consult their oncologists to discuss how emerging clinical developments might influence their future care options.